New At-Home Tests Expand Colon Cancer Screening Options
Finn's Take· TL;DR- At-home blood and stool tests now approved for colorectal cancer screening, expanding options beyond colonoscopy for average-risk adults over 45.
- Blood tests detect tumor DNA but are less effective; recommended annually for those declining other methods, with positive results requiring colonoscopy follow-up.
- New stool DNA and RNA tests offer three-year screening intervals, addressing barriers to screening and enabling earlier cancer detection when most treatable.
Breakthrough in Cancer Prevention
The American Cancer Society has unveiled groundbreaking updates to colorectal cancer screening guidelines, introducing new at-home tests and blood-based screening options that could revolutionize how Americans approach this highly preventable disease. The new recommendations reaffirm that average-risk adults should begin colorectal cancer screening at age 45 and continue through age 75 for those with a life expectancy greater than 10 years .
These changes come at a critical time. The ACS states that screenings are vital as colorectal cancer rates continue to rise in adults under 50 . The updated guidelines reflect a strategic shift toward expanding access and reducing barriers to screening, recognizing that the most effective test is simply the one people actually complete.
New Testing Technologies
The most significant addition is a blood-based test sold under the brand name Shield that was approved by federal regulators in 2024 and is designed to detect tumor DNA in the blood . While blood tests are not as effective as other colorectal cancer screenings and are recommended only for people who decline or can't take other tests , they offer a crucial option for those hesitant about traditional screening methods.
Two new at-home stool tests have also been approved. The next generation-ng-mt-sDNA test (brand name Cologuard), which is an updated version of an already-recommended at-home mt-sDNA test analyzing stool samples for specific DNA markers and hemoglobin . Additionally, a mt-sRNA test (brand name ColoSense) is a new at-home multi-target test that analyzes stool samples for specific RNA markers and hemoglobin .
Screening Schedule and Effectiveness
The blood test and standard fecal testing should be done every year, while DNA-based fecal tests like Cologuard can be taken every three years . These new options complement existing screening methods, including colonoscopy, which remains the gold standard for colorectal cancer screening .
The guidelines emphasize that both tests demonstrate high sensitivity for colorectal cancer and moderate sensitivity for advanced precancerous lesions and are recommended for people over the age of 45 with average risk every 3 years . However, any positive result from a stool-based or blood-based screening should be followed up with a colonoscopy within 6 months .
A Preventable Disease
Colon cancer is one of the few cancers that can be prevented, if doctors are able to detect and remove pre-cancerous polyps inside the colon . This makes screening particularly powerful as a prevention tool, not just early detection.
The expanded options address a fundamental challenge in public health: getting people screened. By offering more screening tools in our guideline update, more eligible adults will be able to participate in lifesaving colorectal cancer testing, helping to close the screening gap and catch more cancers at an earlier, treatable stage . These innovations represent a significant step forward in making cancer prevention more accessible to millions of Americans who might otherwise skip screening altogether.